TLR4-Mediated Sensing of Campylobacter jejuni by Dendritic Cells Is Determined by Sialylation

In Guillain-Barré syndrome (GBS), ganglioside mimicry of Campylobacter jejuni lipo-oligosaccharide (LOS) drives the production of cross-reactive Abs to peripheral nerve gangliosides. We determined whether sialic acid residues in C. jejuni LOS modulate dendritic cell (DC) activation and subsequent B cell proliferation as a possible mechanism for the aberrant humoral immune response in GBS. Highly purified sialylated LOS of C. jejuni isolates from three GBS patients induced human DC maturation and secretion of inflammatory cytokines that were inhibited by anti-TLR4 neutralizing Abs. The extent of TLR4 signaling and DC activation was greater with LOS of the wild type isolates than with nonsialylated LOS of the corresponding sialyltransferase gene knockout (cst-II mutant) strains, indicating that sialylation boosts the DC response to C. jejuni LOS. Supernatants of LOS-activated DCs induced B cell proliferation after cross-linking of surface Igs in the absence of T cells. Lower B cell proliferation indices were found with DC supernatants after DC stimulation with cst-II mutant or neuraminidase desialylated LOS. This study showed that sialylation of C. jejuni LOS enhances human DC activation and subsequent B cell proliferation, which may contribute to the development of cross-reactive anti-ganglioside Abs found in GBS patients following C. jejuni infection.

[1]  K. Hirata,et al.  BAFF aids generation of IgG anti-ganglioside antibodies in response to Campylobacter jejuni lipo-oligosaccharide , 2010, Journal of Neuroimmunology.

[2]  H. Endtz,et al.  The Sialylated Lipooligosaccharide Outer Core in Campylobacter jejuni Is an Important Determinant for Epithelial Cell Invasion , 2008, Infection and Immunity.

[3]  S. Ram,et al.  Human Factor H Interacts Selectively with Neisseria gonorrhoeae and Results in Species-Specific Complement Evasion1 , 2008, The Journal of Immunology.

[4]  N. Yuki,et al.  Axonal Guillain‐Barré syndrome: carbohydrate mimicry and pathophysiology , 2007, Journal of the peripheral nervous system : JPNS.

[5]  C. Visser,et al.  Validation of an ELISA for the diagnosis of recent Campylobacter infections in Guillain-Barré and reactive arthritis patients. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  E. Steyerberg,et al.  A clinical prognostic scoring system for Guillain-Barré syndrome , 2007, The Lancet Neurology.

[7]  Jianjun Li,et al.  Structural Characterization of Campylobacter jejuni Lipooligosaccharide Outer Cores Associated with Guillain-Barré and Miller Fisher Syndromes , 2007, Infection and Immunity.

[8]  H. Willison,et al.  Sialic Acid-Binding Immunoglobulin-Like Lectin 7 Mediates Selective Recognition of Sialylated Glycans Expressed on Campylobacter jejuni Lipooligosaccharides , 2006, Infection and Immunity.

[9]  Soo Young Park,et al.  Gangliosides trigger inflammatory responses via TLR4 in brain glia. , 2006, The American journal of pathology.

[10]  D. Kopecko,et al.  Campylobacter jejuni Induces Maturation and Cytokine Production in Human Dendritic Cells , 2006, Infection and Immunity.

[11]  A. Lanzavecchia,et al.  Toll‐like receptor stimulation as a third signal required for activation of human naive B cells , 2006, European journal of immunology.

[12]  E. S. Baekkevold,et al.  Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. , 2005, Blood.

[13]  H. Willison The immunobiology of Guillain‐Barré syndromes , 2005, Journal of the peripheral nervous system : JPNS.

[14]  Jianjun Li,et al.  The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome. , 2004, The Journal of clinical investigation.

[15]  K. Hirata,et al.  Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Meulstee,et al.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial , 2004, The Lancet.

[17]  P. Crocker,et al.  Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake , 2003, Molecular Microbiology.

[18]  A. Mantovani,et al.  The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. , 2003, Blood.

[19]  J. Brisson,et al.  Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Clark,et al.  Macrophage- and dendritic cell--dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. , 2003, Blood.

[21]  B. Beutler,et al.  Innate immune sensing and its roots: the story of endotoxin , 2003, Nature Reviews Immunology.

[22]  Douglas T. Golenbock,et al.  Lipopolysaccharide Rapidly Traffics to and from the Golgi Apparatus with the Toll-like Receptor 4-MD-2-CD14 Complex in a Process That Is Distinct from the Initiation of Signal Transduction* 210 , 2002, The Journal of Biological Chemistry.

[23]  Kazuro Furukawa,et al.  Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in Campylobacter jejuni Strains Associated with Guillain-Barré Syndrome , 2002, Infection and Immunity.

[24]  B. Nardelli,et al.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL , 2002, Nature Immunology.

[25]  M. Frosch,et al.  Lipooligosaccharide and Polysaccharide Capsule: Virulence Factors of Neisseria meningitidis That Determine Meningococcal Interaction with Human Dendritic Cells , 2002, Infection and Immunity.

[26]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[27]  H. Endtz,et al.  Structure of Campylobacter jejuni Lipopolysaccharides Determines Antiganglioside Specificity and Clinical Features of Guillain-Barré and Miller Fisher Patients , 2002, Infection and Immunity.

[28]  H. Endtz,et al.  A Campylobacter jejuni gene associated with immune-mediated neuropathy , 2001, Nature Medicine.

[29]  P. Ricciardi-Castagnoli,et al.  Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria , 2001, Nature Immunology.

[30]  A. Moran,et al.  Chemical structure of a polysaccharide from Campylobacter jejuni 176.83 (serotype O:41) containing only furanose sugars. , 1999, Carbohydrate research.

[31]  M. Swash,et al.  IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome , 1999, Neurology.

[32]  P. Schmitz,et al.  The spectrum of antecedent infections in Guillain-Barré syndrome , 1998, Neurology.

[33]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[34]  H. Endtz,et al.  Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome , 1997, Journal of Neuroimmunology.

[35]  Christophe Caux,et al.  Dendritic Cells Enhance Growth and Differentiation of CD40-activated B Lymphocytes , 1997, The Journal of experimental medicine.

[36]  H. Endtz,et al.  Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. , 1997, The Journal of infectious diseases.

[37]  M. Blaser,et al.  Campylobacter jejuni and the expanding spectrum of related infections. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  G. Guazzi,et al.  Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy , 1993, Journal of Neuroimmunology.

[39]  M. Swash,et al.  I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. , 1999, Neurology.

[40]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.